Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 505-509

  Soriano, Vincent ^a   Núñez, Marina ^a   Camino, Noria ^a   Maida, Ivana ^a   Barreiro, Pablo ^a   Romero, Miriam ^a   Martín Carbonero, Luz ^a   Garcia Samaniego, Javier ^a   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; FEASIBILITY STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; SIDE EFFECT; VIROLOGY; VIRUS INFECTION; VIRUS INHIBITION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 4344574322     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Martin-Carbonero L, Soriano V, Valencia ME, García-Samaniego H, López M & Gonzales-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Research & Human Retroviruses 2001; 17:1467-1471.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R & Snydman DR. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clinical Infectious Diseases 2001; 32:492-497.
3. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S & Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. Journal of Acquired Immune Deficiency Syndromes 2000; 24:211-217.
4. Lafeuillade A, Hittinger G & Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
5. García-Benayas T, Blanco F & Soriano V. Weight loss in HIV-infected patients. New England Journal of Medicine 2002; 347:1287-1288.
6. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Mauss S, Dieterich D, Poynard T, Cargnel A, Moreno S & Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
7. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A & Rockstroh J. Care of patients with hepatitis C and HIV coinfection: updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
8. Torriani F, Ribeiro R, Gilbert T, Schrenk U, Clauson M, Pacheco D & Perelson A. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. Journal of Infectious Diseases 2003; 188:1498-1507.
9. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales F, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
10. NIH Consensus Development Conference Statement. Management of Hepatitis C. Gastroenterology 2002; 123:2082-2099.
11. Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas J, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jimenez-Nacher I & Soriano V. Pegylated plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1029.
12. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C & Poynard T. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058.
13. Soriano V, Martín-Carbonero L & García-Samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003; 17:751-753.
14. Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, Miralles P, Laguno M, Moreno L, Girón JA, Vogel M, García-Samaniego J, Núñez M, Romero M, Moreno S, de la Cruz JJ & Soriano V. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clinical Infectious Diseases 2004; 38:128-133.
15. Poynard T, Mathurin P, Lai C, Guyader D, Poupon R, Tainturier M, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A & Bedossa P; PANFI-BROSIS Group. A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology 2003; 38:257-265.
16. Soriano V, García-Samaniego J, Bravo R, González J, Castro A, Castilla J, Martinez-Odriozola P, Colmenero M, Carballo E, Suarez D, Rodriguez-Pinero FJ, Moreno A, del Romero J, Pedreira J & Gonzalez-Lahoz J. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clinical Infectious Diseases 1996; 23:585-591.
17. Pérez-Olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, Sánchez-Montero F, Santin M, Guardiola JM, Blanch J, Núñez M, Jiménez-Nacher I, Garcia-Samaniego J & The HCV/HIV Spanish Study Group. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha 2b plus ribavirin. AIDS Research & Human Retroviruses 2003; 19:1083-1089.
18. Torriani F, Rockstroh J, Rodriguez-Torres M, Lissen E, Gonzalez J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Duff F, DePamphilis J, Schrenk UM & Dieterich D. Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alfa-2a + ribavirin vs. interferon-alfa-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, Calif., USA. Abstract 112.
19. Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, Morand P, Salmon D, Pialoux G, Raguin G, Grillot-Courvalin C, Cacoub P & ANRS HC02-RIBAVIC study group. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs. interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, Calif., USA. Abstract 117LB.
20. Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K, Peters M, Koziel M, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C & AIDS Clinical Trials Group A5071 Study Team. A randomized, controlled trial of PEG-interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons: follow-up results of ACTG A5071. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, Calif., USA. Abstract 110.
21. Ballesteros A, Franco S, Fuster D, Planas R, Martínez MA, Acosta L, Sireara G, Salas A, Tor J, Rey-Joly C, Clotet B & Tural C. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
22. Moreno L, Quereda C, Moreno A, Pérez-Elías MJ, Antela A, Casado JL, Dronda F, Mateos M, Bárcena R & Moreno S. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18:67-74.
23. Manns M, Mc Hutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
24. Davis G, Wong J, McHutchison J, Manns M, Harvey J & Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. AIDS 2003; 38:645-652.